



EPI benefits versus COVID–19 risks

HepB3 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children




Hib3 / EPI suspension period: 6 months / vaccine impact: under 5-year-old children

Hib3 / EPI suspension period: 6 months / vaccine impact: under 5-year-old children




EPI benefits versus COVID–19 risks

MCV1 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children



EPI benefits versus COVID–19 risks

MCV2 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children




EPI benefits versus COVID–19 risks

RCV1 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children



EPI benefits versus COVID–19 risks

RotaC / EPI suspension period: 6 months / vaccine impact: under 5–year–old children



benefit–risk ratio



50

40


30

20

10


EPI benefits versus COVID–19 risks

YFV / EPI suspension period: 6 months / vaccine impact: under 5–year–old children




EPI benefits versus COVID–19 risks

MenA / EPI suspension period: 6 months / vaccine impact: under 5–year–old children



EPI benefits versus COVID-19 risks


HPVfem / EPI suspension period: 6 months / vaccine impact: under 5-year-old children



HepB3, Hib3, PCV3, RotaC / EPI suspension period: 6 months / vaccine impact: under 5-year-old chi

benefit-risk ratio

160
120
80
40



EPI benefits versus COVID–19 risks

MCV1, RCV1, MenA, YFV / EPI suspension period: 6 months / vaccine impact: under 5–year–old child

